Vertex Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.03.15	Vertex : FDA Okays Kalydeco For Children With Cystic Fibrosis Ages 2 To 5 (RTTNews)
28.01.15	Vertex Pharma Posts Q4 Loss - Quick Facts (RTTNews)
12.01.15	Vertex Pharma Expects 2015 Kalydeco Revenues Of $560 Mln To $580 Mln In 2015 (RTTNews)
12.01.15	Vertex Pharmaceuticals Outlines 2015 Business Priorities (RTTNews)
29.12.14	FDA Oks Kalydeco To Treat Cystic Fibrosis Patients Who Have R117H Mutation (RTTNews)
19.11.14	Royalty Pharma Buys Cystic Fibrosis Drug Royalties For $3.3 Bln (RTTNews)
19.11.14	Royalty Pharma Buys Royalties On Vertex Pharma'cystic Fibrosis Drug For $3.3 Bln (RTTNews)
05.11.14	Vertex Submits NDA In U.S. And Europe For Lumacaftor Combined With Ivacaftor (RTTNews)
29.10.14	Vertex Pharma Q3 Loss Widens, Tightens 2014 Revenue Outlook (RTTNews)
28.10.14	Vertex Pharma Loss Widens; Tightens FY Guidance - Quick Facts (RTTNews)
22.10.14	TKMR Stays Focused On Ebola, GEVA Sets Work Rolling, FDA Panel Nod For VRTX (RTTNews)
29.07.14	Vertex Pharma Q2 Loss Widens - Quick Facts (RTTNews)
30.06.14	Vertex Submits SNDA For KALYDECO (RTTNews)
27.06.14	Vertex: CHMP Issues Positive Opinion On KALYDECO In Treatment Of Cystic Fibrosis (RTTNews)
24.06.14	Vertex Pharma's Two Phase 3 Studies Meets Primary Endpoint - Quick Facts (RTTNews)
18.06.14	Vertex: Licensing Of VX-787 To Janssen For Treatment Of Influenza (RTTNews)
04.06.14	Vertex Pharma Reports Ivacaftor Study Results - Quick Facts (RTTNews)
02.05.14	Vertex Q1 Loss Narrows, Says Mid-stage Study Of CF Drug Shows Positive Results (RTTNews)
02.05.14	Vertex Pharma Posts Narrower Q1 Loss (RTTNews)
11.02.14	Senior Housing Properties To Buy Two Medical Office Buildings For $1.13 Bln (RTTNews)
29.01.14	Vertex Pharma Turns To Profit In Q4; Issues FY14 Revenue Outlook - Quick Facts (RTTNews)
19.12.13	Pre-market Movers For Dec 19 (FB, ACN, ALIM, PSDV, GRPN, VRTX) (RTTNews)
19.12.13	Vertex Pharma Says Phase 3 Study Of Ivacaftor Fails To Meet Primary Endpoint (RTTNews)
20.11.13	Vertex Sells Incivo Product Royalty Rights To Janssen Pharmaceutica For $152 Mln (RTTNews)
21.10.13	Pre-Market Review: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc. (PR Newswire)
16.10.13	Successful Launches, Upcoming Conference Calls, Signing of Agreements, and Trial Results - Research Report on Vertex, Illumina, Alexion, VIVUS, and Endocyte (PR Newswire)
07.10.13	Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on BioMarin, Alnylam, Vertex, Illumina, and Intrexon (PR Newswire)
30.09.13	Vertex Pharma Submits SNDA To FDA For KALYDECOTM Monotherapy - Quick Facts (RTTNews)
25.09.13	Data Presentations, FDA Approvals, Board Appointments, Updated Clinical Results and New Contracts - Research Report on Vertex, Celgene, NPS Pharmaceuticals, Cyclacel and BioCryst (PR Newswire)
24.09.13	Morning Research: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc. (PR Newswire)
12.09.13	FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec, Vertex, and Illumina (PR Newswire)
11.09.13	Vertex, Ametek Set to Join the S&P 500; Advanced Micro Devices, SAIC to Join S&P MidCap 400; Capstead to Join S&P SmallCap 600 (PR Newswire)
20.08.13	Critical Alerts For Mastercard, Stratasys, Mondelez, Tiffany, and Vertex Released By InvestorsObserver (PR Newswire)
16.08.13	Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc. (PR Newswire)
02.08.13	Investments in R&D Activities and Strong Product Sales Strengthen Companies' Financial Positions - Research Report on Alexion, Amgen, Vertex, Aegerion, and Acadia (PR Newswire)
30.07.13	Vertex Pharma Q2 Loss Narrows, Lowers Top-end Of 2013 Revenue Guidance (RTTNews)
30.07.13	SNTA Enchants, PRGO Picks Up ELN, Tech Glitches Mar CHTP, STXS On High Note (RTTNews)
29.07.13	Vertex Pharmaceuticals Q2 Loss Narrows - Quick Facts (RTTNews)
26.07.13	Gilead Sciences Shares Rise On Higher Q2 Profit, Vertex Drug Setback (RTTNews)
26.07.13	After-market Movers For July 25 (AMZN, SBUX, GILD, EXPE, ZNGA, SWI, TPX, VRTX) (RTTNews)
25.07.13	FDA Places Partial Clinical Hold On Vertex' Ongoing Phase 2 U.S. Study Of VX-135 (RTTNews)
09.07.13	Vertex Kalydeco Gets Australian Regulatory Approval (RTTNews)
25.02.10	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences (Businesswire)
16.02.10	Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013 (Businesswire)
04.02.10	Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs (Businesswire)
11.01.10	Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company (Businesswire)
26.10.09	Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress (Businesswire)
18.09.09	Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences (Businesswire)
04.05.09	Vertex Promotes Dr. Peter Mueller to Global R&D Chief and Chief Science Officer (Businesswire)
25.04.09	Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone

17:56

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

16:06

Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa